Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myasthenia gravis

R Pourmand1

  • 1Department of Neurology, Indiana University School of Medicine, Indianapolis, USA.

Disease-A-Month : DM
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Adult-onset myasthenia gravis is an autoimmune disorder where antibodies attack neuromuscular junctions. Advances in diagnosis and treatments like immunosuppressants and thymectomy have improved patient outcomes significantly.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Message from the editor.

Journal of clinical neuromuscular disease·2008
Same author

Evaluation of a patient presenting with foot drop.

Journal of clinical neuromuscular disease·2008
Same author

Chloroqutne myopathy.

Journal of clinical neuromuscular disease·2008
Same author

Clinical Neuromuscular Highlights of the 46th Annual Scientific Meeting of the American Association of Electrodiagnosis Medicine (AAEM) Vancouver, BC, Canada October 6-9, 1999.

Journal of clinical neuromuscular disease·2008
Same author

Evaluation of a patient presenting with progressive dysarthria and fasciculations of tongue and limb muscles.

Journal of clinical neuromuscular disease·2008
Same author

52nd annual meeting of the American Academy of Neurology, San Diego, California, april 29-may 6, 2000, and the 47th annual scientific meeting of the American Association of Electrodiagnostic Medicine, Philadelphia, Pennsylvania, september 13-16, 2000.

Journal of clinical neuromuscular disease·2008
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
Same journal

Foreword for periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Adult-onset myasthenia gravis is an acquired autoimmune disorder affecting neuromuscular transmission.
  • It involves acetylcholine receptor antibodies attacking the postsynaptic membrane, with 80-90% of generalized cases showing these antibodies.
  • Common symptoms include ptosis, diplopia, dysarthria, and dysphagia, with weakness worsening on exertion.

Purpose of the Study:

  • To review the current understanding of diagnosis and management of adult-onset myasthenia gravis.
  • To highlight advancements in treatment modalities and their impact on patient morbidity and mortality.
  • To emphasize the need for further well-designed, controlled studies.

Main Methods:

  • Diagnosis relies on clinical presentation, neurologic examination, electrophysiologic testing, and immunologic studies.

Related Experiment Videos

  • Differential diagnosis must exclude drug-induced myasthenia gravis and conditions like depression or chronic fatigue syndrome.
  • Treatment involves immunosuppressive/immunomodulating drugs, plasma exchange, and thymectomy.

    • Main Results:

    • Significant progress has been made in understanding and managing myasthenia gravis over the past two decades.
    • New treatments have dramatically decreased morbidity and mortality, improving patient independence.
    • Despite treatment effectiveness, a lack of robust prospective studies remains.

    Conclusions:

    • Myasthenia gravis management has advanced, leading to better patient prognoses.
    • While effective, current therapeutic options require further validation through rigorous research.
    • Continued research is essential to optimize long-term care for myasthenia gravis patients.